prikaz prve stranice dokumenta Difference in Methylation and Expression of Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Mild Cognitive Impairment
  Download
PDF 951.72 KB
Scientific paper - Original scientific paper
Difference in Methylation and Expression of Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Mild Cognitive Impairment
Biomedicines, 11 (2023), 2; 235. https://doi.org/10.3390/biomedicines11020235
Kouter, Katarina; Nikolac Perković, Matea; Nedić Erjavec, Gordana; Miloš, Tina; Tudor, Lucija; Uzun, Suzana; Mimica, Ninoslav; Pivac, Nela; Videtič Paska, Alja

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Kouter, K., Nikolac Perković, M., Nedić Erjavec, G., Miloš, T., Tudor, L., Uzun, S. ... Videtič Paska, A. (2023). Difference in Methylation and Expression of Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Mild Cognitive Impairment. Biomedicines, 11. (2). doi: 10.3390/biomedicines11020235

Kouter, Katarina, et al. "Difference in Methylation and Expression of Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Mild Cognitive Impairment." Biomedicines, vol. 11, no. 2, 2023. https://doi.org/10.3390/biomedicines11020235

Kouter, Katarina, Matea Nikolac Perković, Gordana Nedić Erjavec, Tina Miloš, Lucija Tudor, Suzana Uzun, Ninoslav Mimica, Nela Pivac and Alja Videtič Paska. "Difference in Methylation and Expression of Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Mild Cognitive Impairment." Biomedicines 11, no. 2 (2023). https://doi.org/10.3390/biomedicines11020235

Kouter, K., et al. (2023) 'Difference in Methylation and Expression of Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Mild Cognitive Impairment', Biomedicines, 11(2). doi: 10.3390/biomedicines11020235

Kouter K, Nikolac Perković M, Nedić Erjavec G, Miloš T, Tudor L, Uzun S, and sur.. Difference in Methylation and Expression of Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Mild Cognitive Impairment. Biomedicines [Internet]. 2023 January 17 [cited 2024 April 29];11(2). doi: 10.3390/biomedicines11020235

K. Kouter, et al., "Difference in Methylation and Expression of Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Mild Cognitive Impairment", Biomedicines, vol. 11, no. 2, January 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:205007. [Accessed: 29 April 2024]

Metadata
Title (english)Difference in Methylation and Expression of Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Mild Cognitive Impairment
AuthorKatarina Kouter
AuthorMatea Nikolac Perković
AuthorGordana Nedić Erjavec
AuthorTina Miloš
AuthorLucija Tudor
AuthorSuzana Uzun
AuthorNinoslav Mimica
AuthorNela Pivac
AuthorAlja Videtič Paska
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Psychiatry and Psychological Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Psychiatry
Abstract (english)
Due to the increasing number of progressive dementias in the population, numerous studies are being conducted that seek to determine risk factors, biomarkers and pathological mechanisms that could help to differentiate between normal symptoms of aging, mild cognitive impairment (MCI) and dementia. The aim of this study was to investigate the possible association of levels of BDNF and COMT gene expression and methylation in peripheral blood cells with the development of Alzheimer’s disease (AD). Our results revealed higher expression levels of BDNF (p < 0.001) in MCI subjects compared to individuals diagnosed with AD. However, no difference in COMT gene expression (p = 0.366) was detected. DNA methylation of the CpG islands and other sequences with potential effects on gene expression regulation revealed just one region (BDNF_9) in the BDNF gene (p = 0.078) with marginally lower levels of methylation in the AD compared to MCI subjects. Here, we show that the level of BDNF expression in the periphery is decreased in subjects with AD compared to individuals with MCI. The combined results from the gene expression analysis and DNA methylation analysis point to the potential of BDNF as a marker that could help distinguish between MCI and AD patients.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBiomedicines
Numberingvol. 11, no. 2, 235
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines11020235
URN:NBNurn:nbn:hr:105:205007
Publication2023-01-17
Document URLhttps://www.mdpi.com/2227-9059/11/2/235
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-01-15 08:47:03